MANAMA: The National Health Regulatory Authority (NHRA) has approved Regn-Cov2 for emergency use to treat Covid-19 cases with mild to moderate symptoms. Regn-Cov2 developed by Regeneron and Roche, contains a combination of Casirivimab and Imdevimab (monoclonal antibodies) and is projected to block viral attachment and entry into human cells .
